Hallux Inc
  • Home
  • Approach
  • Leadership
  • News
  • Menu Menu

News

March 27, 2026: Hallux Poster Exhibit Abstract on Dermatophytoma Treatment at 2026 American Academy of Dermatology Annual Meeting

January 14, 2026: FDA Approves IND for Hallux Subungual Gel 42%: A New Approach Enabling Physicians to Treat Toenail Fungus at the Point-of-Care

February 20, 2025 A New Innovative and Transformational Approach to Treatment of Toenail Onychomycosis: An Open Phase 2 Study

February 28, 2023: Hallux Reaches Enrollment Target In Onychomycosis Trial

September 22, 2022: Hallux Inc Opens Third Clinical Site To Evaluate Novel Onychomycosis Product Candidate

July 7, 2022: Hallux Inc Opens Second Clinical Site To Evaluate Novel Onychomycosis Product Candidate

May 18, 2022: Seth M. Birnbaum Joins Pharma Company Hallux Inc. Board Of Directors

April 6, 2022: Hallux Inc. Announces Closing Of $9.4m Series A-2 Financing

January 12, 2022: Hallux Starts Phase 2 Clinical Study Of Novel Subungual Gel For Onychomycosis

November 8, 2016: Hallux Announces Start Of Phase 2 Clinical Trial

 

Hallux Inc

© Copyright 2026 – Hallux Inc

23052 Alcalde Dr, Suite A
Laguna Hills, California 92653, US

Mark@HalluxInc.com
1(800) 690-9989

Linkedin

Scroll to top Scroll to top Scroll to top